Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of BYS10 in advanced solid tumors with RET fusion or mutation
CTR20220752Phase 2Active
- Sponsor
- Baiyunshan Pharmaceutical General Factory
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BYS10 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), thyroid cancer, sponsored by Baiyunshan Pharmaceutical General Factory. Started Apr 2022; status: active.
02
Drugs
BYS10
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)thyroid cancer
Beyond the preview
Go deeper on CTR20220752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220752.